CA2634934A1 - Endometriosis cell targeting peptide and uses thereof - Google Patents

Endometriosis cell targeting peptide and uses thereof Download PDF

Info

Publication number
CA2634934A1
CA2634934A1 CA002634934A CA2634934A CA2634934A1 CA 2634934 A1 CA2634934 A1 CA 2634934A1 CA 002634934 A CA002634934 A CA 002634934A CA 2634934 A CA2634934 A CA 2634934A CA 2634934 A1 CA2634934 A1 CA 2634934A1
Authority
CA
Canada
Prior art keywords
composition
endometriosis
subject
targeting peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002634934A
Other languages
English (en)
French (fr)
Inventor
Michiko Fukuda
Daisuke Aoki
Shiro Nozawa (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2634934A1 publication Critical patent/CA2634934A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
CA002634934A 2005-12-23 2006-12-26 Endometriosis cell targeting peptide and uses thereof Abandoned CA2634934A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75367705P 2005-12-23 2005-12-23
US60/753,677 2005-12-23
PCT/US2006/062601 WO2007076501A2 (en) 2005-12-23 2006-12-26 Endometriosis cell targeting peptide and uses thereof

Publications (1)

Publication Number Publication Date
CA2634934A1 true CA2634934A1 (en) 2007-07-05

Family

ID=38218861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002634934A Abandoned CA2634934A1 (en) 2005-12-23 2006-12-26 Endometriosis cell targeting peptide and uses thereof

Country Status (5)

Country Link
US (2) US9006404B2 (https=)
EP (1) EP1966234A2 (https=)
JP (1) JP2009521512A (https=)
CA (1) CA2634934A1 (https=)
WO (1) WO2007076501A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US8932993B1 (en) 2007-06-11 2015-01-13 Juneau Biosciences, LLC. Method of testing for endometriosis and treatment therefor
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US11287425B2 (en) * 2009-04-22 2022-03-29 Juneau Biosciences, Llc Genetic markers associated with endometriosis and use thereof
US20080305967A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Genetic Markers Associated with Endometriosis and Use Thereof
WO2010017290A1 (en) * 2008-08-05 2010-02-11 The Trustees Of Columbia University In The City Of New York Müllerian inhibiting substance (mis) analogues
US9434991B2 (en) 2013-03-07 2016-09-06 Juneau Biosciences, LLC. Method of testing for endometriosis and treatment therefor
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
US11386065B2 (en) * 2017-01-31 2022-07-12 Salesforce.Com, Inc. Database concurrency control through hash-bucket latching
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
EP3914915A1 (en) * 2019-01-25 2021-12-01 Fertility Lab Sciences, LLC Uterine endometrial fluid for prediction of success in fertility treatment
GB202202919D0 (en) 2022-03-02 2022-04-13 Serac Healthcare Ltd Methods for imaging integrin expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660981A (en) * 1994-06-06 1997-08-26 E. I. Du Pont De Nemours And Company Selection of diagnostic genetic markers in microorganisms and use of a specific marker for detection of salmonella
WO2002016439A2 (en) * 2000-03-07 2002-02-28 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1169064B1 (en) 1999-04-02 2004-03-03 Center For Molecular Medicine And Immunology Method of detecting endometriosis
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
JP2003529361A (ja) * 2000-03-30 2003-10-07 アムジェン インコーポレイテッド ＣＤ２０／ＩｇＥレセプター様分子およびその使用
US20040001823A1 (en) * 2000-04-19 2004-01-01 Yeaman Grant R. Methods of treating endometriosis
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties

Also Published As

Publication number Publication date
EP1966234A2 (en) 2008-09-10
US20080008650A1 (en) 2008-01-10
WO2007076501A3 (en) 2007-11-15
US20150353603A1 (en) 2015-12-10
JP2009521512A (ja) 2009-06-04
US10259844B2 (en) 2019-04-16
US9006404B2 (en) 2015-04-14
WO2007076501A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
US10259844B2 (en) Endometriosis cell targeting peptide and uses thereof
US9783576B2 (en) Compositions and methods for targeted endometriosis treatment
US7259246B2 (en) Immunological detection of prions
Chi et al. Functional domains in nuclear import factor p97 for binding the nuclear localization sequence receptor and the nuclear pore.
US7919466B2 (en) Lymphatic zip codes in tumors and pre-malignant lesions
CN101878223A (zh) 使用notch途径抑制剂治疗癌症的方法
JP5457633B2 (ja) Ｉａｐタンパク質とのｈｓｐ９０タンパク質−タンパク質相互作用を阻害する化合物
US6632616B2 (en) Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
US8877161B2 (en) GM1-like peptides and uses thereof
US20220402980A1 (en) Chromogranin a-derived peptides and uses thereof
JP2004501645A (ja) Ｃ末端Ｅｒｎｓペプチド中の輸送ペプチドおよびその類似体
US8097588B2 (en) Trophinin-binding peptides and uses thereof
Paley et al. Mapping and molecular characterization of novel monoclonal antibodies to conformational epitopes on NH2 and COOH termini of mammalian tryptophanyl-tRNA synthetase reveal link of the epitopes to aggregation and Alzheimer's disease
US20050272130A1 (en) Methods and compositions relating to prion-only transmission of yeast strains
Kim et al. The conserved histidine in epidermal growth factor-like domains of stabilin-2 modulates pH-dependent recognition of phosphatidylserine in apoptotic cells
JP3819712B2 (ja) 細胞内信号伝達を攪乱させる合成ペプチド
KR20180080127A (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
Martin Synthesis and evaluation of synthetic cell surface receptors and related biological probes
Sun Molecular simulations explore disruptive actions of membrane-active peptides in lipid membranes
Shahinian Biophysical and functional properties of lipid-modified proteins and model lipopeptides
HIV YOUNG INVESTIGATORS ABSTRACTS
Henderson Antimicrobial peptides' selectivity and line activity governed by membrane properties

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131227